<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089348</url>
  </required_header>
  <id_info>
    <org_study_id>02/09-AVVA RUS</org_study_id>
    <nct_id>NCT01089348</nct_id>
  </id_info>
  <brief_title>A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis</brief_title>
  <acronym>LF-BV-09</acronym>
  <official_title>Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avva Rus, JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kirov State Medical Academy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kirov Regional clinical Center of Perinatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avva Rus, JSC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II multicenter randomized open-label clinical study that will determine
      whether treatment with Lactofiltrum (orally administered tablets) in combination with
      antibiotic therapy (metronidazole) is effective in women with bacterial vaginosis.
      Lactofiltrum is a composite drug that includes enterosorbent lignin and prebiotic Lactulose.
      It's supposed that supplement of Lactofiltrum to a standard therapy of bacterial vaginosis
      (metronidazole administered orally) improves women's general state, leads to better recovery
      of clinical, microbiological, biochemical and histological features of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported complaints</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
    <description>It's measured by seven ordinal (analog) scales (vaginal itch, vaginal burning, itch of external genitals, burning of external genitals, vaginal discharge, urination disorder,painful intercourse) with minimal value &quot;0&quot; (absent of the complaint-related discomfort) and maximal value &quot;10&quot; (maximal discomfort).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gynaecological examination</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
    <description>It's represented by three ordinal scales with minimal value &quot;0&quot; (&quot;not at all&quot;) and maximal value &quot;3&quot; (&quot;severe&quot;). They are measured by physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microscopy of vaginal discharge</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological examination of vaginal discharge</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH-test of vaginal discharge</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological feces analysis</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine test</measure>
    <time_frame>Days 0, 14 and 44 after start of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Lactofiltrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactofiltrum + Metronidazole</intervention_name>
    <description>Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os</description>
    <arm_group_label>Lactofiltrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 500 mg 1 tablet BID for 7 days per os</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bacterial vaginosis.

        Exclusion Criteria:

          -  pregnancy and breast-feeding;

          -  concomitant infection diseases;

          -  systemic or topical treatment with antibiotics, steroids, immunosuppressive,
             cytostatic or antimetabolite agents by the time of inclusion;

          -  application of intravaginal medicines during participation in the study;

          -  severe diseases;

          -  renal and hepatic failure;

          -  application of pre-, probiotics and antibiotics 2 weeks before inclusion or during
             participation in the study;

          -  participation in other clinical study 1 month before inclusion or during participation
             in the proposed study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyudmila Kobeleva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Avva Rus, JSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey Dvoryanskiy, MD, DrSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirov State Medical Academy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyudmila Kobeleva, MD, PhD</last_name>
    <phone>+7-495-9567559</phone>
    <email>kobeleva@leksir.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nickolay A. Kryuchkov, MD, PhD, MPH</last_name>
    <phone>+7-495-9567559</phone>
    <email>nkryuchkov@leksir.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kirov State Medical Academy</name>
      <address>
        <city>Kirov</city>
        <state>Kirov oblast</state>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Dvoryanskiy, MD, DrSc</last_name>
      <phone>+7-8332-277211</phone>
      <email>dvorsa@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Sergey Dvoryanskiy, MD, DrSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirov Regional Clinical Center of Perinatology</name>
      <address>
        <city>Kirov</city>
        <state>Kirov oblast</state>
        <zip>610048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezhda Yagovkina, MD, PhD</last_name>
      <phone>+7-8332-523639</phone>
      <email>nadezhda-yagovkina@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Nadezhda Yagovkina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Sergey Dvoryanskiy</name_title>
    <organization>Kirov State Medical Academy</organization>
  </responsible_party>
  <keyword>Vaginosis, Bacterial</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Lactofiltrum</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

